Caldolor is owned by Cumberland Pharms.

Caldolor contains Ibuprofen.

Caldolor has a total of 9 drug patents out of which 0 drug patents have expired.

Caldolor was authorised for market use on 11 June, 2009.

Caldolor is available in solution;intravenous dosage forms.

Caldolor can be used as management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof, methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof, methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval, methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity.

The generics of Caldolor are possible to be released after 16 March, 2032.